Kamada Ltd. Overview
Pro stress-test →Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The company serves patients with rare and serious conditions through FDA-approved products and strategic distribution partnerships across 30+ countries.
Strategic Profile
Pro stress-test →The company's strategy focuses on driving profitable growth through four primary pillars: organic growth from commercial activities including six FDA-approved specialty plasma-derived products (KEDRAB, CYTOGAM, GLASSIA, WINRHO SDF, VARIZIG, HEPAGAM B), new business development and M&A opportunities, plasma collection expansion, and development of additional product candidates. Kamada balances commercial stage profitability with innovative pipeline advancement in specialty plasma therapeutics.
Competitive Landscape
Pro stress-test →Kamada competes in the specialty plasma-derived therapeutics market against larger pharma companies that develop immunoglobulins and plasma products. Takeda holds manufacturing and distribution rights for Glassia in major markets (US, Canada, Australia, New Zealand) with Kamada receiving royalties, while Kamada maintains direct distribution and partnerships globally for its portfolio.
Industry Context
Kamada Ltd. operates in Biopharmaceuticals - Specialty Plasma-Derived Therapeutics.
Key facts
Founded: 1990 · Headquarters: Rehovot, Israel (with operations in Hoboken, NJ) · Revenue: $135.8M (9M 2025)